Curi RMB Capital LLC Sells 43,964 Shares of Zoetis Inc. $ZTS

Key Points

• Curi RMB Capital LLC reduced its holdings in Zoetis Inc. by 47.5%, selling 43,964 shares in the first quarter, leaving them with 48,671 shares valued at approximately $8 million.
• Despite minor adjustments by analysts, Zoetis reported better-than-expected quarterly earnings, with an EPS of $1.76 and a revenue of $2.46 billion, outperforming analyst expectations.
• Shares of Zoetis have shown a fluctuation within a one-year range from a low of $139.70 to a high of $200.33, with a current price around $153.13.

Curi RMB Capital LLC lessened its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 47.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,671 shares of the company's stock after selling 43,964 shares during the period. Curi RMB Capital LLC's holdings in Zoetis were worth $8,014,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. 1248 Management LLC bought a new stake in shares of Zoetis during the first quarter worth about $27,000. Saudi Central Bank purchased a new position in Zoetis in the first quarter valued at about $29,000. Cornerstone Planning Group LLC boosted its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares during the period. Finally, Sound Income Strategies LLC raised its position in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $153.13 on Friday. The company's fifty day moving average price is $153.22 and its 200-day moving average price is $157.74. The firm has a market capitalization of $67.86 billion, a price-to-earnings ratio of 26.36, a PEG ratio of 2.45 and a beta of 0.89. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, Zoetis currently has a consensus rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.